Our proven business model continues to set us up for long-term success and the strong earnings performance and a stable topline year-to-date results is continued evidence of this as we have raised our full year revenue and earnings targets.
We anticipate solid earnings and free cash flow growth for the full fiscal year, which continues to increase our capital allocation optionality.
EPS for the quarter was $0.81 per share, flat to the prior year as a result of lower interest expense from debt pay down, offsetting the lower revenue and A&M timing.
Q3 revenue of $238.8 million declined 1.6% on an organic basis versus the prior year, which excludes the effects of foreign currency.
As expected, however, these gains were offset by lower Cough and Cold as well as motion sickness and head lice as these categories faced declines in incidence levels and usage rates related to changes in consumer behavior due to COVID-19.
This important nuance allows us to adjust our brand-building strategy in real time finding additional ways to deliver brand growth.
Utilizing our brand-building toolkit and taking time to understand consumer insights, the goal is to drive long-term growth for our leading brands.